COMBIVENT RESPIMAT
SABASAMA SMI
Ipratropium bromide / Albuterol sulfate · Boehringer Ingelheim
Active Medication & Mechanism
- Ipratropium bromide SAMA20 mcg per actuation
Short-acting muscarinic antagonist (anticholinergic). Blocks vagal cholinergic tone at M3 receptors, reducing bronchospasm in COPD.
- Albuterol sulfate SABA100 mcg per actuation (albuterol base)
Short-acting beta2-adrenergic agonist. Relaxes bronchial smooth muscle by stimulating beta2-receptors, providing rapid bronchodilation.
FDA-Approved Dosing by Indication
// approval varies by strength + age COPD
1/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| 20/100 mcg | Adults (≥18 years) | 1 inhalation four times a day (maximum 6 inhalations in 24 hours) Treatment of bronchospasm associated with COPD in patients requiring more than one bronchodilator. | 80/400 mcg (standard); max 120/600 mcg | FDA Approved |
Asthma
0/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| Any strength | All patients | — | — | Not Approved Combivent Respimat is not indicated for asthma. |
Acute Use
1/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| 20/100 mcg | Adults with COPD | 1 inhalation as needed; maximum 6 inhalations/24h The SABA+SAMA combination provides bronchodilation for acute COPD symptoms. | Maximum 120/600 mcg | FDA Approved |